<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">World J Surg</journal-id><journal-id journal-id-type="iso-abbrev">World J Surg</journal-id><journal-title-group><journal-title>World Journal of Surgery</journal-title></journal-title-group><issn pub-type="ppub">0364-2313</issn><issn pub-type="epub">1432-2323</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29167951</article-id><article-id pub-id-type="pmc">5762793</article-id><article-id pub-id-type="publisher-id">4324</article-id><article-id pub-id-type="doi">10.1007/s00268-017-4324-9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Scientific Report</subject></subj-group></article-categories><title-group><article-title>Radioembolization Versus Bland Embolization for Hepatic Metastases from Small Intestinal Neuroendocrine Tumors: Short-Term Results of a Randomized Clinical Trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name><surname>Elf</surname><given-names>Anna-Karin</given-names></name><address><email>anna-karin.elf@vgregion.se</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Andersson</surname><given-names>Mats</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Henrikson</surname><given-names>Olof</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Jalnefjord</surname><given-names>Oscar</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Ljungberg</surname><given-names>Maria</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Svensson</surname><given-names>Johanna</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Wängberg</surname><given-names>Bo</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Johanson</surname><given-names>Viktor</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9919 9582</institution-id><institution-id institution-id-type="GRID">grid.8761.8</institution-id><institution>Department of Surgery, Sahlgrenska University Hospital and Sahlgrenska Academy, </institution><institution>University of Gothenburg, </institution></institution-wrap>Gothenburg, Sweden </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9919 9582</institution-id><institution-id institution-id-type="GRID">grid.8761.8</institution-id><institution>Department of Radiology, Sahlgrenska University Hospital and Sahlgrenska Academy, </institution><institution>University of Gothenburg, </institution></institution-wrap>Gothenburg, Sweden </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9919 9582</institution-id><institution-id institution-id-type="GRID">grid.8761.8</institution-id><institution>Department of Radiation Physics, Sahlgrenska University Hospital and Sahlgrenska Academy, </institution><institution>University of Gothenburg, </institution></institution-wrap>Gothenburg, Sweden </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9919 9582</institution-id><institution-id institution-id-type="GRID">grid.8761.8</institution-id><institution>Department of Oncology, Sahlgrenska University Hospital and Sahlgrenska Academy, </institution><institution>University of Gothenburg, </institution></institution-wrap>Gothenburg, Sweden </aff></contrib-group><pub-date pub-type="epub"><day>22</day><month>11</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>22</day><month>11</month><year>2017</year></pub-date><pub-date pub-type="ppub"><year>2018</year></pub-date><volume>42</volume><issue>2</issue><fpage>506</fpage><lpage>513</lpage><permissions><copyright-statement>© The Author(s) 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><abstract id="Abs1"><sec><title><offsets xml_i="5191" xml_f="5201" txt_i="11" txt_f="21">Background</offsets></title><p id="Par1"><offsets xml_i="5222" xml_f="5283" txt_i="22" txt_f="83">Radioembolization (RE) with intra-arterial administration of </offsets><sup><offsets xml_i="5288" xml_f="5290" txt_i="83" txt_f="85">90</offsets></sup><offsets xml_i="5296" xml_f="5773" txt_i="85" txt_f="562">Y microspheres is a promising technique for the treatment of liver metastases from small intestinal neuroendocrine tumors (SI-NET) not amenable to surgery or local ablation. However, studies comparing RE to other loco-regional therapies are lacking. The aim of this randomized study was to compare the therapeutic response and safety after RE and bland hepatic arterial embolization (HAE), and to investigate early therapy-induced changes with diffusion-weighted MRI (DWI-MRI).</offsets></p></sec><sec><title><offsets xml_i="5795" xml_f="5802" txt_i="564" txt_f="571">Methods</offsets></title><p id="Par2"><offsets xml_i="5823" xml_f="6175" txt_i="572" txt_f="924">Eleven patients were included in a prospective randomized controlled pilot study, six assigned to RE and five to HAE. Response according to RECIST 1.1 using MRI or CT at 3 and 6 months post-treatment was recorded as well as changes in DWI-MRI parameters after 1 month. Data on biochemical tumor response, toxicity, and side effects were also collected.</offsets></p></sec><sec><title><offsets xml_i="6197" xml_f="6204" txt_i="926" txt_f="933">Results</offsets></title><p id="Par3"><offsets xml_i="6225" xml_f="6361" txt_i="934" txt_f="1070">Three months after treatment, all patients in the HAE group showed partial response according to RECIST while none in the RE group did (</offsets><italic><offsets xml_i="6369" xml_f="6370" txt_i="1070" txt_f="1071">p</offsets></italic><offsets xml_i="6379" xml_f="6577" txt_i="1071" txt_f="1269"> = 0.0022). After 6 months, the response rates were 4/5 (80%) and 2/6 (33%) in the HAE and RE groups, respectively (NS). DWI-MRI metrics could not predict RECIST response, but lower pretreatment ADC</offsets><sub><offsets xml_i="6582" xml_f="6591" txt_i="1269" txt_f="1278">(120–800)</offsets></sub><offsets xml_i="6597" xml_f="6612" txt_i="1278" txt_f="1293"> and larger ADC</offsets><sub><offsets xml_i="6617" xml_f="6624" txt_i="1293" txt_f="1300">(0–800)</offsets></sub><offsets xml_i="6630" xml_f="6730" txt_i="1300" txt_f="1400"> increase at 1 month were related to larger decrease in tumor diameter when all tumors were counted.</offsets></p></sec><sec><title><offsets xml_i="6752" xml_f="6762" txt_i="1402" txt_f="1412">Conclusion</offsets></title><p id="Par4"><offsets xml_i="6783" xml_f="7122" txt_i="1413" txt_f="1752">HAE resulted in significantly higher RECIST response after 3 months, but no difference compared to RE remained after 6 months. These preliminary findings indicate that HAE remains a safe option for the treatment of liver metastases from SI-NET, and further studies are needed to establish the role of RE and the predictive value of MR-DWI.</offsets></p></sec><sec><title><offsets xml_i="7144" xml_f="7177" txt_i="1754" txt_f="1787">Electronic supplementary material</offsets></title><p><offsets xml_i="7188" xml_f="7323" txt_i="1788" txt_f="1923">The online version of this article (10.1007/s00268-017-4324-9) contains supplementary material, which is available to authorized users.</offsets></p></sec></abstract><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© Société Internationale de Chirurgie 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title><offsets xml_i="7600" xml_f="7612" txt_i="1932" txt_f="1944">Introduction</offsets></title><p id="Par5"><offsets xml_i="7633" xml_f="7962" txt_i="1945" txt_f="2274">The primary tumors of small intestinal neuroendocrine tumors (SI-NETs) can almost always be radically resected by surgery, often together with the regional lymph node metastases. Hepatic metastases are common, and surgical resection is suitable only in a minority of cases calling for other loco-regional treatment alternatives [</offsets><xref ref-type="bibr" rid="CR1"><offsets xml_i="7994" xml_f="7995" txt_i="2274" txt_f="2275">1</offsets></xref><offsets xml_i="8002" xml_f="8399" txt_i="2275" txt_f="2672">]. Local ablative therapies using radiofrequency or microwaves are an option if the metastases are few, small, and suitably localized. In other cases, loco-regional endovascular therapies, such as hepatic arterial embolization (HAE) or chemoembolization (TACE), are considered. The mainstay for treating widespread liver metastases at our unit has been HAE with polyvinyl alcohol (PVA) particles [</offsets><xref ref-type="bibr" rid="CR2"><offsets xml_i="8431" xml_f="8432" txt_i="2672" txt_f="2673">2</offsets></xref><offsets xml_i="8439" xml_f="8664" txt_i="2673" txt_f="2898">]. However, the treatment is often associated with side effects due to liver ischemia, and recurrence may occur. Recently, radioembolization (RE), involving transcatheter arterial delivery of 20–60 µm microspheres containing </offsets><sup><offsets xml_i="8669" xml_f="8671" txt_i="2898" txt_f="2900">90</offsets></sup><offsets xml_i="8677" xml_f="9010" txt_i="2900" txt_f="3233">Y radioisotope into the tumor microvasculature, has emerged as a promising tool in the management of hepatic metastases from NET. RE is considered to have less acute and subacute toxicity than HAE, as it avoids liver ischemia. However, studies documenting the safety and efficacy of RE largely represent retrospective cohort series [</offsets><xref ref-type="bibr" rid="CR3"><offsets xml_i="9042" xml_f="9043" txt_i="3233" txt_f="3234">3</offsets></xref><offsets xml_i="9050" xml_f="9051" txt_i="3234" txt_f="3235">–</offsets><xref ref-type="bibr" rid="CR9"><offsets xml_i="9083" xml_f="9084" txt_i="3235" txt_f="3236">9</offsets></xref><offsets xml_i="9091" xml_f="9190" txt_i="3236" txt_f="3335">], while prospective studies comparing RE to other loco-regional therapies such as HAE are lacking.</offsets></p><p id="Par6"><offsets xml_i="9207" xml_f="9349" txt_i="3336" txt_f="3478">Currently accepted guidelines for assessing treatment response in solid tumors include response evaluation criteria in solid tumors (RECIST) [</offsets><xref ref-type="bibr" rid="CR10"><offsets xml_i="9382" xml_f="9384" txt_i="3478" txt_f="3480">10</offsets></xref><offsets xml_i="9391" xml_f="9393" txt_i="3480" txt_f="3482">, </offsets><xref ref-type="bibr" rid="CR11"><offsets xml_i="9426" xml_f="9428" txt_i="3482" txt_f="3484">11</offsets></xref><offsets xml_i="9435" xml_f="9874" txt_i="3484" txt_f="3923">]. However, these morphological criteria may not be conclusive until several months following therapy. Earlier evaluation of response to therapy would allow alternative therapy sooner, with optimized management of the individual patient. Diffusion-weighted imaging (DWI) is a functional MR imaging method that provides insight into the tumor microenvironment and can potentially be used as an early surrogate biomarker for tumor response [</offsets><xref ref-type="bibr" rid="CR12"><offsets xml_i="9907" xml_f="9909" txt_i="3923" txt_f="3925">12</offsets></xref><offsets xml_i="9916" xml_f="9918" txt_i="3925" txt_f="3927">, </offsets><xref ref-type="bibr" rid="CR13"><offsets xml_i="9951" xml_f="9953" txt_i="3927" txt_f="3929">13</offsets></xref><offsets xml_i="9960" xml_f="9962" txt_i="3929" txt_f="3931">].</offsets></p><p id="Par7"><offsets xml_i="9979" xml_f="10403" txt_i="3932" txt_f="4356">Here, we present the preliminary results of a randomized phase II study where the primary end point was to compare the treatment response, according to RECIST, of hepatic metastases at 3 months after RE or HAE. Secondary aims were to study the radiological response at 6 months, the biochemical response, and toxicity, and to evaluate the usefulness of early changes in DWI parameters in predicting later treatment response.</offsets></p></sec><sec id="Sec2" sec-type="materials|methods"><title><offsets xml_i="10464" xml_f="10485" txt_i="4358" txt_f="4379">Materials and methods</offsets></title><sec id="Sec3"><title><offsets xml_i="10515" xml_f="10523" txt_i="4380" txt_f="4388">Patients</offsets></title><p id="Par8"><offsets xml_i="10544" xml_f="10913" txt_i="4389" txt_f="4758">Inclusion criteria were multiple SI-NET liver metastases, grade 1 or 2, not accessible to curative resection or ablation, and elevated serum chromogranin A (CgA) and/or 24 h urinary 5-HIAA excretion (dU-5HIAA). All patients were under somatostatin analogue (SSA) treatment, and primary surgery with removal of all extrahepatic tumors had been performed in all patients.</offsets></p><p id="Par9"><offsets xml_i="10930" xml_f="11137" txt_i="4759" txt_f="4966">Exclusion criteria were remaining extrahepatic metastases, previous loco-regional or systemic anti-tumoral treatment (except SSA), impaired liver function or tumor volume exceeding 50% of total liver volume.</offsets></p><p id="Par10"><offsets xml_i="11155" xml_f="11457" txt_i="4967" txt_f="5269">Before treatments, all patients but one were investigated with DWI-MRI. The remaining patient could not undergo MRI due to cardiac pacemaker and was evaluated with CT. DWI-MRI was repeated 1 month after treatment followed by response evaluation with MRI or CT according to RECIST 1.1 at 3 and 6 months.</offsets></p><p id="Par11"><offsets xml_i="11475" xml_f="11551" txt_i="5270" txt_f="5346">The study was approved by the Ethical Review Board of Gothenburg University.</offsets></p></sec><sec id="Sec4"><title><offsets xml_i="11583" xml_f="11604" txt_i="5348" txt_f="5369">RE and HAE procedures</offsets></title><p id="Par12"><offsets xml_i="11626" xml_f="11718" txt_i="5370" txt_f="5462">Radioembolization was performed with bilobar infusion in a standard manner in all patients [</offsets><xref ref-type="bibr" rid="CR9"><offsets xml_i="11750" xml_f="11751" txt_i="5462" txt_f="5463">9</offsets></xref><offsets xml_i="11758" xml_f="11879" txt_i="5463" txt_f="5584">]. Protective coil embolization was used when necessary to prevent non-target embolization. The administered activity of </offsets><sup><offsets xml_i="11884" xml_f="11886" txt_i="5584" txt_f="5586">90</offsets></sup><offsets xml_i="11892" xml_f="11970" txt_i="5586" txt_f="5664">Y resin microspheres (SIR-spheres™) was calculated using the partition model [</offsets><xref ref-type="bibr" rid="CR14"><offsets xml_i="12003" xml_f="12005" txt_i="5664" txt_f="5666">14</offsets></xref><offsets xml_i="12012" xml_f="12014" txt_i="5666" txt_f="5668">].</offsets></p><p id="Par13"><offsets xml_i="12032" xml_f="12339" txt_i="5669" txt_f="5976">HAE was performed by infusion of PVA particles (45–150 μm) into the right or left hepatic artery until stasis was achieved. The right liver lobe was treated first, embolizing the remaining left lobe at a second session, about 6 weeks later. No other anti-tumoral therapy was started during the study period.</offsets></p></sec><sec id="Sec5"><title><offsets xml_i="12371" xml_f="12397" txt_i="5978" txt_f="6004">Magnetic resonance imaging</offsets></title><p id="Par14"><offsets xml_i="12419" xml_f="12631" txt_i="6005" txt_f="6217">The MRI measurements were performed on a Gyroscan Achieva dStream 3 T Release 5.1.7 (Philips Medical Systems, Eindhoven, the Netherlands). The examination included T2W and T1W scans, and a DWI scan with multiple </offsets><italic><offsets xml_i="12639" xml_f="12640" txt_i="6217" txt_f="6218">b</offsets></italic><offsets xml_i="12649" xml_f="12684" txt_i="6218" txt_f="6253">-values (0, 120, 350, 575, 800 s/mm</offsets><sup><offsets xml_i="12689" xml_f="12690" txt_i="6253" txt_f="6254">2</offsets></sup><offsets xml_i="12696" xml_f="12934" txt_i="6254" txt_f="6492">). At baseline and at the 3 and 6 months follow-up examinations, a T1-weighted dynamic contrast-enhanced sequence in the late arterial and portal venous phases was added to the protocol (for details see Electronic Supplementary Material).</offsets></p></sec><sec id="Sec6"><title><offsets xml_i="12966" xml_f="12980" txt_i="6494" txt_f="6508">Image analysis</offsets></title><p id="Par15"><offsets xml_i="13002" xml_f="13363" txt_i="6509" txt_f="6870">Up to five liver metastases, with lesion diameters larger than 1 cm, were analyzed per patient. Multiple free-hand regions of interest (ROIs) were drawn to encompass the whole volume of the metastases on DWI-MRI images. The relative ADC values at 1 month, compared to pretreatment baseline values, were calculated. As a control, a circular ROI of minimum 120 mm</offsets><sup><offsets xml_i="13368" xml_f="13369" txt_i="6870" txt_f="6871">2</offsets></sup><offsets xml_i="13375" xml_f="13478" txt_i="6871" txt_f="6974"> was placed on normal-appearing splenic parenchyma (for details see Electronic Supplementary Material).</offsets></p></sec><sec id="Sec7"><title><offsets xml_i="13510" xml_f="13544" txt_i="6976" txt_f="7010">Assessment of therapeutic response</offsets></title><p id="Par16"><offsets xml_i="13566" xml_f="13688" txt_i="7011" txt_f="7133">Response evaluation was performed by MRI or CT at 3 and 6 months after treatment, according to the RECIST 1.1 guidelines [</offsets><xref ref-type="bibr" rid="CR11"><offsets xml_i="13721" xml_f="13723" txt_i="7133" txt_f="7135">11</offsets></xref><offsets xml_i="13730" xml_f="14002" txt_i="7135" txt_f="7407">]. For every patient, two target lesions, which appeared best measurable and representative of the patient’s overall tumor load at the baseline MRI/CT, were chosen in accordance with RECIST criteria using the “Tumor Tracking” module at the IntelliSpace-Portal workstation.</offsets></p><p id="Par17"><offsets xml_i="14020" xml_f="14120" txt_i="7408" txt_f="7508">Biochemical tumor markers CgA in serum and dU-5HIAA were measured at 3 and 6 months after treatment.</offsets></p><p id="Par18"><offsets xml_i="14138" xml_f="14576" txt_i="7509" txt_f="7947">Therapeutic response at 3 and 6 months after treatment was also determined on a lesion-by-lesion basis by evaluating changes in size of a total of 39 tumors. The measurements of the lesion diameters (LD = longest diameter) were averaged across all MR sequences. The relative tumor size at different times after treatment was calculated by comparing it with pretreatment baseline values (for details see Electronic Supplementary Material).</offsets></p></sec><sec id="Sec8"><title><offsets xml_i="14608" xml_f="14616" txt_i="7949" txt_f="7957">Toxicity</offsets></title><p id="Par19"><offsets xml_i="14638" xml_f="14935" txt_i="7958" txt_f="8255">Toxicity was assessed weekly during the first month after treatment by measuring hemoglobin, white blood count, and platelets. At the same time points, liver-specific toxicity was assessed by measuring ASAT, ALAT, ALP, and bilirubin. Blood sampling was repeated at 3 and 6 months after treatments.</offsets></p></sec><sec id="Sec9"><title><offsets xml_i="14967" xml_f="14987" txt_i="8257" txt_f="8277">Statistical analysis</offsets></title><p id="Par20"><offsets xml_i="15009" xml_f="15440" txt_i="8278" txt_f="8709">Response rates according to RECIST1.1 were estimated with binomial proportions and compared by Fisher’s exact test using the MedCalc statistics package (MedCalc Software, Ostend, Belgium). Linear mixed models were used to test for difference between changes in ADC parameters and for linear correlation between ADC parameters and change in size following treatment using MATLAB 2016b (MathWorks Inc, Natick, MA, USA). Mann–Whitney </offsets><italic><offsets xml_i="15448" xml_f="15449" txt_i="8709" txt_f="8710">U</offsets></italic><offsets xml_i="15458" xml_f="15553" txt_i="8710" txt_f="8805"> test or Wilcoxon signed-rank test were used to compare differences in continuous variables. A </offsets><italic><offsets xml_i="15561" xml_f="15562" txt_i="8805" txt_f="8806">p</offsets></italic><offsets xml_i="15571" xml_f="15631" txt_i="8806" txt_f="8863"> value of &lt;0.05 was considered statistically significant.</offsets></p></sec></sec><sec id="Sec10" sec-type="results"><title><offsets xml_i="15689" xml_f="15696" txt_i="8866" txt_f="8873">Results</offsets></title><p id="Par21"><offsets xml_i="15718" xml_f="15893" txt_i="8874" txt_f="9049">Between January 2014 and September 2016, 11 patients with irresectable liver metastases from SI-NET, not suitable for local ablative treatments, were randomly assigned to RE (</offsets><italic><offsets xml_i="15901" xml_f="15902" txt_i="9049" txt_f="9050">n</offsets></italic><offsets xml_i="15911" xml_f="15925" txt_i="9050" txt_f="9064"> = 6) or HAE (</offsets><italic><offsets xml_i="15933" xml_f="15934" txt_i="9064" txt_f="9065">n</offsets></italic><offsets xml_i="15943" xml_f="16024" txt_i="9065" txt_f="9146"> = 5). Median age at enrollment was 67 years, and three patients were men (Table </offsets><xref rid="Tab1" ref-type="table"><offsets xml_i="16058" xml_f="16059" txt_i="9146" txt_f="9147">1</offsets></xref><offsets xml_i="16066" xml_f="16293" txt_i="9147" txt_f="9371">). All patients had &gt; 5 metastases, and a total of 36 lesions, which could be consistently assessed throughout all MRI examinations, were analyzed on a lesion-by-lesion basis. A median activity of 1.4 (range 1.1–1.8) GBq of </offsets><sup><offsets xml_i="16298" xml_f="16300" txt_i="9371" txt_f="9373">90</offsets></sup><offsets xml_i="16306" xml_f="16825" txt_i="9373" txt_f="9892">Y was given to patients receiving RE. The first radiological response evaluation, DWI-MRI, was performed after a median time of 32 days (range 22–55 days) after RE or the first HAE treatment (the right lobe). The 2nd and 3rd evaluations were performed after a median time of 90 and 195 days, respectively (range 84–118 and 166–251 days), after treatment. However, one of the patients, with a pacemaker, was assessed with CT only, and another patient treated with HAE failed to undergo DWI-MRI at the 1-month time point.</offsets><table-wrap id="Tab1"><label><offsets xml_i="16854" xml_f="16861" txt_i="9892" txt_f="9899">Table 1</offsets></label><caption><p><offsets xml_i="16881" xml_f="16987" txt_i="9899" txt_f="10005">Baseline data: Baseline clinical and tumor characteristics of the study population randomized to RE or HAE</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"></th><th align="left"><offsets xml_i="17088" xml_f="17102" txt_i="10006" txt_f="10020">All patients (</offsets><italic><offsets xml_i="17110" xml_f="17111" txt_i="10020" txt_f="10021">n</offsets></italic><offsets xml_i="17120" xml_f="17126" txt_i="10021" txt_f="10027"> = 11)</offsets></th><th align="left"><offsets xml_i="17148" xml_f="17171" txt_i="10027" txt_f="10050">Patients receiving RE (</offsets><italic><offsets xml_i="17179" xml_f="17180" txt_i="10050" txt_f="10051">n</offsets></italic><offsets xml_i="17189" xml_f="17194" txt_i="10051" txt_f="10056"> = 6)</offsets></th><th align="left"><offsets xml_i="17216" xml_f="17240" txt_i="10056" txt_f="10080">Patients receiving HAE (</offsets><italic><offsets xml_i="17248" xml_f="17249" txt_i="10080" txt_f="10081">n</offsets></italic><offsets xml_i="17258" xml_f="17263" txt_i="10081" txt_f="10086"> = 5)</offsets></th><th align="left"><offsets xml_i="17285" xml_f="17286" txt_i="10086" txt_f="10087">
</offsets><italic><offsets xml_i="17294" xml_f="17295" txt_i="10087" txt_f="10088">p</offsets></italic><offsets xml_i="17304" xml_f="17310" txt_i="10088" txt_f="10094"> value</offsets></th></tr></thead><tbody><tr><td align="left"><offsets xml_i="17356" xml_f="17382" txt_i="10094" txt_f="10120">Age, years, median (range)</offsets></td><td align="left"><offsets xml_i="17404" xml_f="17414" txt_i="10121" txt_f="10131">67 (40–79)</offsets></td><td align="left"><offsets xml_i="17436" xml_f="17448" txt_i="10132" txt_f="10144">66.5 (40–79)</offsets></td><td align="left"><offsets xml_i="17470" xml_f="17480" txt_i="10145" txt_f="10155">67 (51–79)</offsets></td><td char="." align="char"><offsets xml_i="17511" xml_f="17516" txt_i="10156" txt_f="10161">0.65*</offsets></td></tr><tr><td align="left"><offsets xml_i="17547" xml_f="17555" txt_i="10162" txt_f="10170">Male sex</offsets></td><td align="left"><offsets xml_i="17577" xml_f="17578" txt_i="10171" txt_f="10172">3</offsets></td><td align="left"><offsets xml_i="17600" xml_f="17601" txt_i="10173" txt_f="10174">2</offsets></td><td align="left"><offsets xml_i="17623" xml_f="17624" txt_i="10175" txt_f="10176">1</offsets></td><td char="." align="char"><offsets xml_i="17655" xml_f="17661" txt_i="10177" txt_f="10183">1.00**</offsets></td></tr><tr><td align="left"><offsets xml_i="17692" xml_f="17734" txt_i="10184" txt_f="10226">Number of lesions analyzed, median (range)</offsets></td><td align="left"><offsets xml_i="17756" xml_f="17763" txt_i="10227" txt_f="10234">4 (1–5)</offsets></td><td align="left"><offsets xml_i="17785" xml_f="17792" txt_i="10235" txt_f="10242">5 (2–5)</offsets></td><td align="left"><offsets xml_i="17814" xml_f="17821" txt_i="10243" txt_f="10250">3 (1–5)</offsets></td><td char="." align="char"><offsets xml_i="17852" xml_f="17857" txt_i="10251" txt_f="10256">0.11*</offsets></td></tr><tr><td align="left"><offsets xml_i="17888" xml_f="17909" txt_i="10257" txt_f="10278">Median LD, mm (range)</offsets></td><td align="left"><offsets xml_i="17931" xml_f="17943" txt_i="10279" txt_f="10291">20.3 (13–55)</offsets></td><td align="left"><offsets xml_i="17965" xml_f="17977" txt_i="10292" txt_f="10304">20.3 (13–50)</offsets></td><td align="left"><offsets xml_i="17999" xml_f="18011" txt_i="10305" txt_f="10317">19.9 (13–55)</offsets></td><td char="." align="char"><offsets xml_i="18042" xml_f="18047" txt_i="10318" txt_f="10323">0.92*</offsets></td></tr><tr><td align="left"><offsets xml_i="18078" xml_f="18129" txt_i="10324" txt_f="10375">Median sum of LD of metastases analyzed, mm (range)</offsets></td><td align="left"><offsets xml_i="18151" xml_f="18162" txt_i="10376" txt_f="10387">77 (30–170)</offsets></td><td align="left"><offsets xml_i="18184" xml_f="18195" txt_i="10388" txt_f="10399">89 (35–170)</offsets></td><td align="left"><offsets xml_i="18217" xml_f="18228" txt_i="10400" txt_f="10411">74 (30–170)</offsets></td><td char="." align="char"><offsets xml_i="18259" xml_f="18264" txt_i="10412" txt_f="10417">0.27*</offsets></td></tr><tr><td align="left"><offsets xml_i="18295" xml_f="18314" txt_i="10418" txt_f="10437">Median baseline ADC</offsets><sub><offsets xml_i="18319" xml_f="18328" txt_i="10437" txt_f="10446">(120–800)</offsets></sub><offsets xml_i="18334" xml_f="18338" txt_i="10446" txt_f="10450">, 10</offsets><sup><offsets xml_i="18343" xml_f="18345" txt_i="10450" txt_f="10452">−3</offsets></sup><offsets xml_i="18351" xml_f="18353" txt_i="10452" txt_f="10454">mm</offsets><sup><offsets xml_i="18358" xml_f="18359" txt_i="10454" txt_f="10455">2</offsets></sup><offsets xml_i="18365" xml_f="18375" txt_i="10455" txt_f="10465">/s (range)</offsets></td><td align="left"><offsets xml_i="18397" xml_f="18411" txt_i="10466" txt_f="10480">0.73 (0.5–1.3)</offsets></td><td align="left"><offsets xml_i="18433" xml_f="18447" txt_i="10481" txt_f="10495">0.78 (0.5–1.3)</offsets></td><td align="left"><offsets xml_i="18469" xml_f="18483" txt_i="10496" txt_f="10510">0.68 (0.5–1.0)</offsets></td><td char="." align="char"><offsets xml_i="18514" xml_f="18519" txt_i="10511" txt_f="10516">0.15*</offsets></td></tr><tr><td align="left"><offsets xml_i="18550" xml_f="18590" txt_i="10517" txt_f="10554">Primary tumor, grade 1 (Ki-67 &lt; 2%) (</offsets><italic><offsets xml_i="18598" xml_f="18599" txt_i="10554" txt_f="10555">n</offsets></italic><offsets xml_i="18608" xml_f="18609" txt_i="10555" txt_f="10556">)</offsets></td><td align="left"><offsets xml_i="18631" xml_f="18632" txt_i="10557" txt_f="10558">7</offsets></td><td align="left"><offsets xml_i="18654" xml_f="18655" txt_i="10559" txt_f="10560">5</offsets></td><td align="left"><offsets xml_i="18677" xml_f="18678" txt_i="10561" txt_f="10562">2</offsets></td><td char="." align="char"><offsets xml_i="18709" xml_f="18715" txt_i="10563" txt_f="10569">0.24**</offsets></td></tr><tr><td align="left"><offsets xml_i="18746" xml_f="18784" txt_i="10570" txt_f="10608">Primary tumor, grade 2 (Ki-67 3–20%) (</offsets><italic><offsets xml_i="18792" xml_f="18793" txt_i="10608" txt_f="10609">n</offsets></italic><offsets xml_i="18802" xml_f="18803" txt_i="10609" txt_f="10610">)</offsets></td><td align="left"><offsets xml_i="18825" xml_f="18826" txt_i="10611" txt_f="10612">4</offsets></td><td align="left"><offsets xml_i="18848" xml_f="18849" txt_i="10613" txt_f="10614">1</offsets></td><td align="left"><offsets xml_i="18871" xml_f="18872" txt_i="10615" txt_f="10616">3</offsets></td><td char="." align="char"><offsets xml_i="18903" xml_f="18909" txt_i="10617" txt_f="10623">0.24**</offsets></td></tr><tr><td align="left"><offsets xml_i="18940" xml_f="18975" txt_i="10624" txt_f="10659">Median dU-5HIAA (µmol/24 h) (range)</offsets></td><td align="left"><offsets xml_i="18997" xml_f="19009" txt_i="10660" txt_f="10672">110 (21–270)</offsets></td><td align="left"><offsets xml_i="19031" xml_f="19042" txt_i="10673" txt_f="10684">97 (54–130)</offsets></td><td align="left"><offsets xml_i="19064" xml_f="19076" txt_i="10685" txt_f="10697">110 (21–270)</offsets></td><td char="." align="char"><offsets xml_i="19107" xml_f="19112" txt_i="10698" txt_f="10703">0.93*</offsets></td></tr><tr><td align="left"><offsets xml_i="19143" xml_f="19168" txt_i="10704" txt_f="10729">Median CgA (µg/L) (range)</offsets></td><td align="left"><offsets xml_i="19190" xml_f="19203" txt_i="10730" txt_f="10743">231 (81–1890)</offsets></td><td align="left"><offsets xml_i="19225" xml_f="19237" txt_i="10744" txt_f="10756">162 (81–470)</offsets></td><td align="left"><offsets xml_i="19259" xml_f="19273" txt_i="10757" txt_f="10771">384 (115–1890)</offsets></td><td char="." align="char"><offsets xml_i="19304" xml_f="19309" txt_i="10772" txt_f="10777">0.36*</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="19355" xml_f="19370" txt_i="10778" txt_f="10793">* Mann–Whitney </offsets><italic><offsets xml_i="19378" xml_f="19379" txt_i="10793" txt_f="10794">U</offsets></italic><offsets xml_i="19388" xml_f="19393" txt_i="10794" txt_f="10799"> test</offsets></p><p><offsets xml_i="19400" xml_f="19422" txt_i="10800" txt_f="10822">** Fisher’s exact test</offsets></p></table-wrap-foot></table-wrap><offsets xml_i="19457" xml_f="19458" txt_i="10823" txt_f="10824">
</offsets></p><sec id="Sec11"><title><offsets xml_i="19485" xml_f="19500" txt_i="10825" txt_f="10840">RECIST response</offsets></title><p id="Par22"><offsets xml_i="19522" xml_f="19657" txt_i="10841" txt_f="10976">At 3 months after treatment, no responders were seen in the RE group while all patients in the HAE group showed partial response (PR) (</offsets><italic><offsets xml_i="19665" xml_f="19666" txt_i="10976" txt_f="10977">p</offsets></italic><offsets xml_i="19675" xml_f="19913" txt_i="10977" txt_f="11215"> = 0.0022). After 6 months, two patients in the RE group showed PR while one patient in the HAE group had progressed compared to nadir at 3 months, resulting in no remaining significant difference between the groups (Fisher’s exact test, </offsets><italic><offsets xml_i="19921" xml_f="19922" txt_i="11215" txt_f="11216">p</offsets></italic><offsets xml_i="19931" xml_f="19946" txt_i="11216" txt_f="11231"> = 0.24) (Fig. </offsets><xref rid="Fig1" ref-type="fig"><offsets xml_i="19978" xml_f="19979" txt_i="11231" txt_f="11232">1</offsets></xref><offsets xml_i="19986" xml_f="19988" txt_i="11232" txt_f="11234">).</offsets><fig id="Fig1"><label><offsets xml_i="20010" xml_f="20016" txt_i="11234" txt_f="11240">Fig. 1</offsets></label><caption><p><offsets xml_i="20036" xml_f="20337" txt_i="11240" txt_f="11541">RECIST response in target lesions in the treated liver at 3 months (dark gray staples) and 6 months (light gray staples) post-treatment. Solid black line indicates threshold for partial response (PR). At 3 months, no responders were seen in the RE group while all patients in the HAE group showed PR (</offsets><italic><offsets xml_i="20345" xml_f="20346" txt_i="11541" txt_f="11542">p</offsets></italic><offsets xml_i="20355" xml_f="20365" txt_i="11542" txt_f="11552"> = 0.0022)</offsets></p></caption><graphic xlink:href="268_2017_4324_Fig1_HTML" id="MO1"></graphic></fig><offsets xml_i="20450" xml_f="20451" txt_i="11553" txt_f="11554">
</offsets></p></sec><sec id="Sec12"><title><offsets xml_i="20484" xml_f="20504" txt_i="11556" txt_f="11576">Biochemical response</offsets></title><p id="Par23"><offsets xml_i="20526" xml_f="20900" txt_i="11577" txt_f="11951">Biochemical markers, CgA and 5HIAA, decreased in most patients after 3 and 6 months. The data were rather divergent, and there were no statistically significant differences between the treatment groups. The median reduction in CgA level after 3 months was 52% in the HAE group and 29% in the RE group. Corresponding values after 6 months were 47 and 44%, respectively (Fig. </offsets><xref rid="Fig2" ref-type="fig"><offsets xml_i="20932" xml_f="20933" txt_i="11951" txt_f="11952">2</offsets></xref><offsets xml_i="20940" xml_f="21120" txt_i="11952" txt_f="12132">). The median reduction in 5HIAA excretion after 3 months was 43% in the HAE group and 25% in the RE group. Corresponding values after 6 months were 36 and 43%, respectively (Fig. </offsets><xref rid="Fig3" ref-type="fig"><offsets xml_i="21152" xml_f="21153" txt_i="12132" txt_f="12133">3</offsets></xref><offsets xml_i="21160" xml_f="21162" txt_i="12133" txt_f="12135">).</offsets><fig id="Fig2"><label><offsets xml_i="21184" xml_f="21190" txt_i="12135" txt_f="12141">Fig. 2</offsets></label><caption><p><offsets xml_i="21210" xml_f="21513" txt_i="12141" txt_f="12444">Relative change in CgA levels compared to baseline values, at 3 months (dark gray staples) and at 6 months (light gray staples) after treatment with HAE or RE. The median decrease in CgA levels at 3 months was 52% in the HAE group and 29% in the RE group, and 47 and 44%, respectively, at 6 months (NS, </offsets><italic><offsets xml_i="21521" xml_f="21522" txt_i="12444" txt_f="12445">p</offsets></italic><offsets xml_i="21531" xml_f="21562" txt_i="12445" txt_f="12476"> = 0.42 and 0.66, respectively)</offsets></p></caption><graphic xlink:href="268_2017_4324_Fig2_HTML" id="MO2"></graphic></fig><offsets xml_i="21647" xml_f="21648" txt_i="12477" txt_f="12478">
</offsets><fig id="Fig3"><label><offsets xml_i="21670" xml_f="21676" txt_i="12478" txt_f="12484">Fig. 3</offsets></label><caption><p><offsets xml_i="21696" xml_f="21995" txt_i="12484" txt_f="12783">Relative change in dU-5HIAA compared to baseline values, at 3 months (dark gray staples) and at 6 months (light gray staples) after treatment with HAE or RE. The median decrease in dU-5HIAA at 3 months was 43% in the HAE group and 25% in the RE group, and 36 and 43%, respectively, at 6 months (NS, </offsets><italic><offsets xml_i="22003" xml_f="22004" txt_i="12783" txt_f="12784">p</offsets></italic><offsets xml_i="22013" xml_f="22128" txt_i="12784" txt_f="12896"> &gt; 0.05). Patient R5 showed no change in dU-5HIAA values at all time points, hence no visible bars in the figure</offsets></p></caption><graphic xlink:href="268_2017_4324_Fig3_HTML" id="MO3"></graphic></fig><offsets xml_i="22213" xml_f="22214" txt_i="12897" txt_f="12898">
</offsets></p></sec><sec id="Sec13"><title><offsets xml_i="22247" xml_f="22302" txt_i="12900" txt_f="12955">Tumor size response and correlation with DWI assessment</offsets></title><p id="Par24"><offsets xml_i="22324" xml_f="22463" txt_i="12956" txt_f="13095">The median pretreatment LD was 20 mm (range 13–55 mm) when evaluating all 36 tumors. In the 10 patients examined with MRI, pretreatment ADC</offsets><sub><offsets xml_i="22468" xml_f="22477" txt_i="13095" txt_f="13104">(120–800)</offsets></sub><offsets xml_i="22483" xml_f="22585" txt_i="13104" txt_f="13206"> values were significantly negatively correlated with treatment response (decreasing LD) at 6 months (</offsets><italic><offsets xml_i="22593" xml_f="22594" txt_i="13206" txt_f="13207">k</offsets></italic><offsets xml_i="22603" xml_f="22610" txt_i="13207" txt_f="13214"> = 45, </offsets><italic><offsets xml_i="22618" xml_f="22619" txt_i="13214" txt_f="13215">p</offsets></italic><offsets xml_i="22628" xml_f="22665" txt_i="13215" txt_f="13249"> &lt; 0.01). The mean increase in ADC</offsets><sub><offsets xml_i="22670" xml_f="22679" txt_i="13249" txt_f="13258">(120–800)</offsets></sub><offsets xml_i="22685" xml_f="22811" txt_i="13258" txt_f="13384"> at 1 month was 40% after HAE and 11% after RE, although the difference between treatments was not statistically significant (</offsets><italic><offsets xml_i="22819" xml_f="22820" txt_i="13384" txt_f="13385">p</offsets></italic><offsets xml_i="22829" xml_f="22938" txt_i="13385" txt_f="13494"> = 0.08). However, there was a statistically significant correlation between the relative increase in the ADC</offsets><sub><offsets xml_i="22943" xml_f="22950" txt_i="13494" txt_f="13501">(0–800)</offsets></sub><offsets xml_i="22956" xml_f="23027" txt_i="13501" txt_f="13572"> values at 1 month and treatment response (decreasing LD) at 3 months (</offsets><italic><offsets xml_i="23035" xml_f="23036" txt_i="13572" txt_f="13573">k</offsets></italic><offsets xml_i="23045" xml_f="23054" txt_i="13573" txt_f="13582"> = −0.2, </offsets><italic><offsets xml_i="23062" xml_f="23063" txt_i="13582" txt_f="13583">p</offsets></italic><offsets xml_i="23072" xml_f="23090" txt_i="13583" txt_f="13598"> &lt; 0.05) (Fig. </offsets><xref rid="Fig4" ref-type="fig"><offsets xml_i="23122" xml_f="23123" txt_i="13598" txt_f="13599">4</offsets></xref><offsets xml_i="23130" xml_f="23307" txt_i="13599" txt_f="13776">). After 3 and 6 months, the relative (compared to baseline) median LD was significantly smaller in metastases treated with HAE than in patients treated with RE, 45 versus 89% (</offsets><italic><offsets xml_i="23315" xml_f="23316" txt_i="13776" txt_f="13777">p</offsets></italic><offsets xml_i="23325" xml_f="23357" txt_i="13777" txt_f="13806"> &lt; 0.001) and 39 versus 81% (</offsets><italic><offsets xml_i="23365" xml_f="23366" txt_i="13806" txt_f="13807">p</offsets></italic><offsets xml_i="23375" xml_f="23408" txt_i="13807" txt_f="13837"> &lt; 0.001), respectively (Fig. </offsets><xref rid="Fig5" ref-type="fig"><offsets xml_i="23440" xml_f="23441" txt_i="13837" txt_f="13838">5</offsets></xref><offsets xml_i="23448" xml_f="23450" txt_i="13838" txt_f="13840">).</offsets><fig id="Fig4"><label><offsets xml_i="23472" xml_f="23478" txt_i="13840" txt_f="13846">Fig. 4</offsets></label><caption><p><offsets xml_i="23498" xml_f="23521" txt_i="13846" txt_f="13869">Correlation between ADC</offsets><sub><offsets xml_i="23526" xml_f="23533" txt_i="13869" txt_f="13876">(0–800)</offsets></sub><offsets xml_i="23539" xml_f="23583" txt_i="13876" txt_f="13920"> at 1 month and decrease in LD at 3 months (</offsets><italic><offsets xml_i="23591" xml_f="23592" txt_i="13920" txt_f="13921">k</offsets></italic><offsets xml_i="23601" xml_f="23610" txt_i="13921" txt_f="13930"> = −0.2, </offsets><italic><offsets xml_i="23618" xml_f="23619" txt_i="13930" txt_f="13931">p</offsets></italic><offsets xml_i="23628" xml_f="23888" txt_i="13931" txt_f="14188"> &lt; 0.05) in individual tumors in patients treated with RE (R) and HAE (H), respectively. Values are given as percent of pretreatment value. The blue, red, and black lines show the regression line for HAE patients, RE patients, and all patients, respectively</offsets></p></caption><graphic xlink:href="268_2017_4324_Fig4_HTML" id="MO4"></graphic></fig><offsets xml_i="23973" xml_f="23974" txt_i="14189" txt_f="14190">
</offsets><fig id="Fig5"><label><offsets xml_i="23996" xml_f="24002" txt_i="14190" txt_f="14196">Fig. 5</offsets></label><caption><p><offsets xml_i="24022" xml_f="24277" txt_i="14196" txt_f="14451">Relative individual tumor diameters after treatment. At 3 months after treatment, the relative (compared to baseline) median tumor diameter in measured lesions was significantly smaller after HAE, 45% (range 19–58%), compared to RE, 89% (range 54–106%), (</offsets><italic><offsets xml_i="24285" xml_f="24286" txt_i="14451" txt_f="14452">p</offsets></italic><offsets xml_i="24295" xml_f="24448" txt_i="14452" txt_f="14602"> &lt; 0.001). The difference remained after 6 months, when the relative tumor diameter was 39% (range 7–86%) after HAE and 81% (range 31–103%) after RE (</offsets><italic><offsets xml_i="24456" xml_f="24457" txt_i="14602" txt_f="14603">p</offsets></italic><offsets xml_i="24466" xml_f="24478" txt_i="14603" txt_f="14612"> &lt; 0.001)</offsets></p></caption><graphic xlink:href="268_2017_4324_Fig5_HTML" id="MO5"></graphic></fig><offsets xml_i="24563" xml_f="24564" txt_i="14613" txt_f="14614">
</offsets></p><p id="Par25"><offsets xml_i="24582" xml_f="24613" txt_i="14615" txt_f="14646">No difference in the median ADC</offsets><sub><offsets xml_i="24618" xml_f="24625" txt_i="14646" txt_f="14653">(0–800)</offsets></sub><offsets xml_i="24631" xml_f="24638" txt_i="14653" txt_f="14660"> or ADC</offsets><sub><offsets xml_i="24643" xml_f="24652" txt_i="14660" txt_f="14669">(120–800)</offsets></sub><offsets xml_i="24658" xml_f="24743" txt_i="14669" txt_f="14754"> values measured in the spleen before and after treatment was found (data not shown).</offsets></p></sec><sec id="Sec14"><title><offsets xml_i="24776" xml_f="24784" txt_i="14756" txt_f="14764">Toxicity</offsets></title><p id="Par26"><offsets xml_i="24806" xml_f="25124" txt_i="14765" txt_f="15083">Overall toxicity from both treatments was low, and blood cell count at 6 months did not differ from baseline. Liver-specific evaluation showed that RE patients had slightly increased median levels of alkaline phosphatase compared to HAE patients at 6 months (2.8 µkat/L, range 1.6–15.5 vs. 1.45 µkat/L, range 1.0–2.1, </offsets><italic><offsets xml_i="25132" xml_f="25133" txt_i="15083" txt_f="15084">p</offsets></italic><offsets xml_i="25142" xml_f="25234" txt_i="15084" txt_f="15173"> &lt; 0.05), but no significant differences in liver enzymes or bilirubin values were found.</offsets></p><p id="Par27"><offsets xml_i="25252" xml_f="25458" txt_i="15174" txt_f="15380">One patient in the HAE group developed post-treatment cholecystitis, which caused a prolonged hospital stay of 10 days. Median hospital stay after HAE was 4 days (range 4–10 days), which was significantly (</offsets><italic><offsets xml_i="25466" xml_f="25467" txt_i="15380" txt_f="15381">p</offsets></italic><offsets xml_i="25476" xml_f="25539" txt_i="15381" txt_f="15444"> = 0.024) longer than after RE (median 2 days, range 2–6 days).</offsets></p></sec></sec><sec id="Sec15" sec-type="discussion"><title><offsets xml_i="25600" xml_f="25610" txt_i="15447" txt_f="15457">Discussion</offsets></title><p id="Par28"><offsets xml_i="25632" xml_f="25893" txt_i="15458" txt_f="15719">For SI-NET patients with metastases that cannot be resected by surgery, other treatment options are needed. Systemic radiotherapy with radiolabeled somatostatin analogues (PRRT) has recently proved to be superior to treatment with somatostatin analogues alone [</offsets><xref ref-type="bibr" rid="CR15"><offsets xml_i="25926" xml_f="25928" txt_i="15719" txt_f="15721">15</offsets></xref><offsets xml_i="25935" xml_f="26230" txt_i="15721" txt_f="16016">]. But accumulated radiotoxicity is a concern, and repeated full-dose PRRT can rarely be performed. When the metastatic burden is limited to the liver, liver-directed therapy is preferable. At least HAE can be performed repeatedly, and neither HAE nor RE prevents future use of PRRT, if needed [</offsets><xref ref-type="bibr" rid="CR16"><offsets xml_i="26263" xml_f="26265" txt_i="16016" txt_f="16018">16</offsets></xref><offsets xml_i="26272" xml_f="26274" txt_i="16018" txt_f="16020">].</offsets></p><p id="Par29"><offsets xml_i="26292" xml_f="26667" txt_i="16021" txt_f="16396">This is the first randomized prospective study that compares HAE and RE for the treatment of hepatic SI-NET metastases. Response evaluation according to RECIST utilizes the longest lesion diameter (LD) and specified threshold diameter changes. However, the appearance and size of liver metastases from NET may vary between MR sequences and phases of contrast administration [</offsets><xref ref-type="bibr" rid="CR17"><offsets xml_i="26700" xml_f="26702" txt_i="16396" txt_f="16398">17</offsets></xref><offsets xml_i="26709" xml_f="26801" txt_i="16398" txt_f="16490">]. It is currently somewhat unclear which sequence is the best for measuring these lesions [</offsets><xref ref-type="bibr" rid="CR18"><offsets xml_i="26834" xml_f="26836" txt_i="16490" txt_f="16492">18</offsets></xref><offsets xml_i="26843" xml_f="27168" txt_i="16492" txt_f="16817">]. Peri-tumoral edema on T2W imaging and peri-tumoral enhancement on dynamic contrast imaging may cause overestimation of the diameter measured. We hypothesized that averaging LD across all imaging sequences at one time point would compensate for these differences, optimizing the conditions for accurate response evaluation.</offsets></p><p id="Par30"><offsets xml_i="27186" xml_f="27381" txt_i="16818" txt_f="17013">In this study, the RECIST response rate after radioembolization for metastatic NET was 33% at 6 months, which compares well with other studies that have shown a response rate between 22 and 63% [</offsets><xref ref-type="bibr" rid="CR4"><offsets xml_i="27413" xml_f="27414" txt_i="17013" txt_f="17014">4</offsets></xref><offsets xml_i="27421" xml_f="27422" txt_i="17014" txt_f="17015">–</offsets><xref ref-type="bibr" rid="CR6"><offsets xml_i="27454" xml_f="27455" txt_i="17015" txt_f="17016">6</offsets></xref><offsets xml_i="27462" xml_f="27464" txt_i="17016" txt_f="17018">, </offsets><xref ref-type="bibr" rid="CR19"><offsets xml_i="27497" xml_f="27499" txt_i="17018" txt_f="17020">19</offsets></xref><offsets xml_i="27506" xml_f="27507" txt_i="17020" txt_f="17021">–</offsets><xref ref-type="bibr" rid="CR22"><offsets xml_i="27540" xml_f="27542" txt_i="17021" txt_f="17023">22</offsets></xref><offsets xml_i="27549" xml_f="27957" txt_i="17023" txt_f="17431">]. We noted that compared to HAE, the response after RE was delayed and that the target lesions continued to decrease in size from 3 to 6 months post-treatment. At 6 months, no significant difference in the RECIST response remained. A similar trend in the response pattern of the biochemical tumor markers CgA and 5HIAA was noted. Such a delayed treatment response has also been observed by Fidelman et al. [</offsets><xref ref-type="bibr" rid="CR23"><offsets xml_i="27990" xml_f="27992" txt_i="17431" txt_f="17433">23</offsets></xref><offsets xml_i="27999" xml_f="28078" txt_i="17433" txt_f="17512">] who reported a median time to maximum response of 11 months in a study using </offsets><sup><offsets xml_i="28083" xml_f="28085" txt_i="17512" txt_f="17514">90</offsets></sup><offsets xml_i="28091" xml_f="28148" txt_i="17514" txt_f="17571">Y glass microspheres for the treatment of metastatic NET.</offsets></p><p id="Par31"><offsets xml_i="28166" xml_f="28169" txt_i="17572" txt_f="17575">ADC</offsets><sub><offsets xml_i="28174" xml_f="28183" txt_i="17575" txt_f="17584">(120–800)</offsets></sub><offsets xml_i="28189" xml_f="28332" txt_i="17584" txt_f="17727"> primarily reflects diffusion, and both animal models and clinical studies have shown that lower ADC values in tumors indicate high viability [</offsets><xref ref-type="bibr" rid="CR12"><offsets xml_i="28365" xml_f="28367" txt_i="17727" txt_f="17729">12</offsets></xref><offsets xml_i="28374" xml_f="28471" txt_i="17729" txt_f="17826">] and a relative lack of necrosis, facilitating the intratumoral delivery of therapeutic agents [</offsets><xref ref-type="bibr" rid="CR24"><offsets xml_i="28504" xml_f="28506" txt_i="17826" txt_f="17828">24</offsets></xref><offsets xml_i="28513" xml_f="28515" txt_i="17828" txt_f="17830">, </offsets><xref ref-type="bibr" rid="CR25"><offsets xml_i="28548" xml_f="28550" txt_i="17830" txt_f="17832">25</offsets></xref><offsets xml_i="28557" xml_f="28599" txt_i="17832" txt_f="17874">]. The finding that lower pretreatment ADC</offsets><sub><offsets xml_i="28604" xml_f="28613" txt_i="17874" txt_f="17883">(120–800)</offsets></sub><offsets xml_i="28619" xml_f="28831" txt_i="17883" txt_f="18095"> was related to improved response (larger decrease of LD at 6 months) represents a well-known association between pretreatment ADC and response that has been reported for NET as well as for other tumor entities [</offsets><xref ref-type="bibr" rid="CR26"><offsets xml_i="28864" xml_f="28866" txt_i="18095" txt_f="18097">26</offsets></xref><offsets xml_i="28873" xml_f="28874" txt_i="18097" txt_f="18098">–</offsets><xref ref-type="bibr" rid="CR28"><offsets xml_i="28907" xml_f="28909" txt_i="18098" txt_f="18100">28</offsets></xref><offsets xml_i="28916" xml_f="28918" txt_i="18100" txt_f="18102">].</offsets></p><p id="Par32"><offsets xml_i="28936" xml_f="28987" txt_i="18103" txt_f="18154">While HAE resulted in a significant increase in ADC</offsets><sub><offsets xml_i="28992" xml_f="29001" txt_i="18154" txt_f="18163">(120–800)</offsets></sub><offsets xml_i="29007" xml_f="29322" txt_i="18163" txt_f="18478"> at 1 month, RE did not. The reason for this is not clear, although the radiotoxic effect certainly is delayed compared to the more immediate ischemic effect of bland embolization. Another study of RE found no early ADC increase in responding colorectal liver metastases, which they associated with cellular edema [</offsets><xref ref-type="bibr" rid="CR29"><offsets xml_i="29355" xml_f="29357" txt_i="18478" txt_f="18480">29</offsets></xref><offsets xml_i="29364" xml_f="29474" txt_i="18480" txt_f="18590">]. Signs of an inflammatory response with peri-tumoral edema after RE have also been described on CT imaging [</offsets><xref ref-type="bibr" rid="CR30"><offsets xml_i="29507" xml_f="29509" txt_i="18590" txt_f="18592">30</offsets></xref><offsets xml_i="29516" xml_f="29708" txt_i="18592" txt_f="18784">]. However, it cannot be ruled out that the lack of a significant increase in diffusion at 1 month after RE was due to inadequate anti-tumor effect or suboptimal timing of the DWI measurement.</offsets></p><p id="Par33"><offsets xml_i="29726" xml_f="29874" txt_i="18785" txt_f="18933">DWI analysis at 1 month after treatment could not predict the RECIST response in an individual patient in this small study. A larger increase in ADC</offsets><sub><offsets xml_i="29879" xml_f="29886" txt_i="18933" txt_f="18940">(0–800)</offsets></sub><offsets xml_i="29892" xml_f="30018" txt_i="18940" txt_f="19066"> was, however, related to improved response (larger decrease of LD at 3 months) when analyzing all measured lesions. Since ADC</offsets><sub><offsets xml_i="30023" xml_f="30028" txt_i="19066" txt_f="19071">0–800</offsets></sub><offsets xml_i="30034" xml_f="30053" txt_i="19071" txt_f="19090">, as opposed to ADC</offsets><sub><offsets xml_i="30058" xml_f="30065" txt_i="19090" txt_f="19097">120–800</offsets></sub><offsets xml_i="30071" xml_f="30334" txt_i="19097" txt_f="19360">, is affected by both diffusion and pseudodiffusion caused by microscopic circulation, this result may indicate that changes in microperfusion after embolization are involved in the therapeutic process. Although there are contradictory results in the literature [</offsets><xref ref-type="bibr" rid="CR31"><offsets xml_i="30367" xml_f="30369" txt_i="19360" txt_f="19362">31</offsets></xref><offsets xml_i="30376" xml_f="30446" txt_i="19362" txt_f="19432">], this finding is in accordance with the suggestion of Kukuk et al. [</offsets><xref ref-type="bibr" rid="CR26"><offsets xml_i="30479" xml_f="30481" txt_i="19432" txt_f="19434">26</offsets></xref><offsets xml_i="30488" xml_f="30624" txt_i="19434" txt_f="19570">] that there is an increase in microperfusion secondary to a decrease in interstitial fluid pressure (IFP) in responding NET metastases.</offsets></p><p id="Par34"><xref ref-type="bibr" rid="CR32"><offsets xml_i="30675" xml_f="30677" txt_i="19571" txt_f="19573">32</offsets></xref><offsets xml_i="30684" xml_f="30686" txt_i="19573" txt_f="19575">].</offsets></p><p id="Par35"><offsets xml_i="30704" xml_f="30887" txt_i="19576" txt_f="19759">Strength of the study is the prospective randomized design. To our knowledge, this is the first randomized trial comparing outcome after RE versus HAE in patients with metastatic NET.</offsets></p><p id="Par36"><offsets xml_i="30905" xml_f="31313" txt_i="19760" txt_f="20168">In conclusion, in this randomized pilot study comparing RE and HAE for liver metastatic SI-NET, all metastases decreased in size after 3 months, but the decrease was significantly larger in patients treated with HAE. However, no significant difference in RECIST response between groups remained after 6 months, suggesting a delayed anatomical response after treatment with RE. Although lower pretreatment ADC</offsets><sub><offsets xml_i="31318" xml_f="31327" txt_i="20168" txt_f="20177">(120–800)</offsets></sub><offsets xml_i="31333" xml_f="31360" txt_i="20177" txt_f="20204"> and larger increase in ADC</offsets><sub><offsets xml_i="31365" xml_f="31372" txt_i="20204" txt_f="20211">(0–800)</offsets></sub><offsets xml_i="31378" xml_f="31801" txt_i="20211" txt_f="20634"> at 1 month were related to improved response (decrease in tumor diameter), at 3 and 6 months respectively, no DWI-MRI threshold for the prediction of response according to RECIST could be defined. These preliminary findings indicate that HAE remains a safe option for treatment of liver metastases from SI-NET, and further studies are needed to establish the role of RE and the predictive value of DWI-MRI in these tumors.</offsets></p></sec><sec sec-type="supplementary-material"><title><offsets xml_i="31857" xml_f="31890" txt_i="20636" txt_f="20669">Electronic supplementary material</offsets></title><sec id="Sec16"><p><offsets xml_i="31917" xml_f="31977" txt_i="20670" txt_f="20730">Below is the link to the electronic supplementary material.
</offsets><supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="268_2017_4324_MOESM1_ESM.docx"><caption><p><offsets xml_i="32101" xml_f="32138" txt_i="20730" txt_f="20767">Supplementary material 1 (DOCX 13 kb)</offsets></p></caption></media></supplementary-material><offsets xml_i="32185" xml_f="32186" txt_i="20768" txt_f="20769">
</offsets></p></sec></sec></body><back><fn-group><fn><p><bold>Electronic supplementary material</bold></p><p>The online version of this article (10.1007/s00268-017-4324-9) contains supplementary material, which is available to authorized users.</p></fn><fn><p>Anna-Karin Elf and Mats Andersson have contributed equally to the completion of this manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>
<sup>90</sup>Y resin microspheres (SIR-spheres™) were generously supplied by Sirtex. Professor Peter Bernhardt, Department of Radiation Physics at Sahlgrenska University Hospital is greatly appreciated for his contribution during the planning and performance of this study including responsibility of the dosimetry.</p></ack><notes notes-type="COI-statement"><title>Compliance with ethical standards</title><sec id="FPar1"><title>Conflict of interest</title><p id="Par37">The authors declare that they have no conflict of interest.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahlman</surname><given-names>H</given-names></name><name><surname>Westeberg</surname><given-names>G</given-names></name><name><surname>Wängberg</surname><given-names>B</given-names></name><etal></etal></person-group><article-title>Treatment of liver metastases of carcinoid tumors</article-title><source>World J Surg</source><year>1996</year><volume>20</volume><fpage>196</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1007/s002689900030</pub-id><pub-id pub-id-type="pmid">8661817</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swärd</surname><given-names>C</given-names></name><name><surname>Johanson</surname><given-names>V</given-names></name><name><surname>Nieveen van Dijkum</surname><given-names>E</given-names></name><etal></etal></person-group><article-title>Prolonged survival after hepatic artery embolization in patients with midgut carcinoid syndrome</article-title><source>Br J Surg</source><year>2009</year><volume>96</volume><fpage>517</fpage><lpage>521</lpage><pub-id pub-id-type="doi">10.1002/bjs.6587</pub-id><pub-id pub-id-type="pmid">19358175</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajekar</surname><given-names>H</given-names></name><name><surname>Bogammana</surname><given-names>K</given-names></name><name><surname>Stubbs</surname><given-names>RS</given-names></name></person-group><article-title>Selective internal radiation therapy for gastrointestinal neuroendocrine tumour liver metastases: a new and effective modality for treatment</article-title><source>Int J Hepatol</source><year>2011</year><pub-id pub-id-type="pmid">22164335</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kennedy</surname><given-names>AS</given-names></name><name><surname>Dezarn</surname><given-names>WA</given-names></name><name><surname>McNeillie</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>Radioembolization for unresectable neuroendocrine hepatic metastases using resin <sup>90</sup>Y-microspheres: early results in 148 patients</article-title><source>Am J Clin Oncol</source><year>2008</year><volume>31</volume><fpage>271</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1097/COC.0b013e31815e4557</pub-id><pub-id pub-id-type="pmid">18525307</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>King</surname><given-names>J</given-names></name><name><surname>Quinn</surname><given-names>R</given-names></name><name><surname>Glenn</surname><given-names>DM</given-names></name><etal></etal></person-group><article-title>Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases</article-title><source>Cancer</source><year>2008</year><volume>113</volume><fpage>921</fpage><lpage>929</lpage><pub-id pub-id-type="doi">10.1002/cncr.23685</pub-id><pub-id pub-id-type="pmid">18618495</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rhee</surname><given-names>TK</given-names></name><name><surname>Lewandowski</surname><given-names>RJ</given-names></name><name><surname>Liu</surname><given-names>DM</given-names></name><etal></etal></person-group><article-title><sup>90</sup>Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience</article-title><source>Ann Surg</source><year>2008</year><volume>247</volume><fpage>1029</fpage><lpage>1035</lpage><pub-id pub-id-type="doi">10.1097/SLA.0b013e3181728a45</pub-id><pub-id pub-id-type="pmid">18520231</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>Z</given-names></name><name><surname>Paz-Fumagalli</surname><given-names>R</given-names></name><name><surname>Frey</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>Single-institution experience of radioembolization with yttrium-90 microspheres for unresectable metastatic neuroendocrine liver tumors</article-title><source>J Gastroenterol Hepatol</source><year>2017</year><volume>32</volume><fpage>1617</fpage><lpage>1623</lpage><pub-id pub-id-type="doi">10.1111/jgh.13752</pub-id><pub-id pub-id-type="pmid">28132407</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Memon</surname><given-names>K</given-names></name><name><surname>Lewandowski</surname><given-names>RJ</given-names></name><name><surname>Mulcahy</surname><given-names>MF</given-names></name><etal></etal></person-group><article-title>Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2012</year><volume>83</volume><fpage>887</fpage><lpage>894</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2011.07.041</pub-id><pub-id pub-id-type="pmid">22137020</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barbier</surname><given-names>CE</given-names></name><name><surname>Garske-Román</surname><given-names>U</given-names></name><name><surname>Sandström</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Selective internal radiation therapy in patients with progressive neuroendocrine liver metastases</article-title><source>Eur J Nucl Med Mol Imaging</source><year>2016</year><volume>43</volume><fpage>425</fpage><lpage>1431</lpage><pub-id pub-id-type="doi">10.1007/s00259-015-3264-6</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Therasse</surname><given-names>P</given-names></name><name><surname>Arbuck</surname><given-names>SG</given-names></name><name><surname>Eisenhauer</surname><given-names>EA</given-names></name><etal></etal></person-group><article-title>New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada</article-title><source>J Natl Cancer Inst</source><year>2000</year><volume>92</volume><fpage>205</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1093/jnci/92.3.205</pub-id><pub-id pub-id-type="pmid">10655437</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eisenhauer</surname><given-names>EA</given-names></name><name><surname>Therasse</surname><given-names>P</given-names></name><name><surname>Bogaerts</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)</article-title><source>Eur J Cancer</source><year>2009</year><volume>45</volume><fpage>228</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2008.10.026</pub-id><pub-id pub-id-type="pmid">19097774</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Padhani</surname><given-names>AR</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Mu-Koh</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations</article-title><source>Neoplasia</source><year>2009</year><volume>11</volume><fpage>102</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1593/neo.81328</pub-id><pub-id pub-id-type="pmid">19186405</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thoeny</surname><given-names>HC</given-names></name><name><surname>Ross</surname><given-names>BD</given-names></name></person-group><article-title>Predicting and monitoring cancer treatment response with DW-MRI</article-title><source>J Magn Reson Imaging</source><year>2010</year><volume>32</volume><fpage>2</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1002/jmri.22167</pub-id><pub-id pub-id-type="pmid">20575076</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernardini</surname><given-names>M</given-names></name><name><surname>Smadja</surname><given-names>C</given-names></name><name><surname>Faraggi</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Liver selective internal radiation therapy with <sup>90</sup>Y resin microspheres: comparison between pre-treatment activity calculation methods</article-title><source>Phys Med</source><year>2014</year><volume>30</volume><fpage>752</fpage><lpage>764</lpage><pub-id pub-id-type="doi">10.1016/j.ejmp.2014.05.004</pub-id><pub-id pub-id-type="pmid">24923844</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strosberg</surname><given-names>J</given-names></name><name><surname>El-Haddad</surname><given-names>G</given-names></name><name><surname>Wolin</surname><given-names>E</given-names></name><etal></etal></person-group><article-title>Phase 3 Trial of <sup>177</sup>Lu-Dotatate for midgut neuroendocrine tumors</article-title><source>N Engl J Med</source><year>2017</year><volume>376</volume><fpage>125</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1607427</pub-id><pub-id pub-id-type="pmid">28076709</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamiditabar</surname><given-names>M</given-names></name><name><surname>Ali</surname><given-names>M</given-names></name><name><surname>Bolek</surname><given-names>L</given-names></name></person-group><article-title>Safety and effectiveness of <sup>177</sup>Lu-DOTATATE peptide receptor radionuclide therapy after regional hepatic embolization in patients with somatostatin-expressing neuroendocrine tumors</article-title><source>Clin Nucl Med</source><year>2017</year><volume>42</volume><fpage>822</fpage><lpage>828</lpage><pub-id pub-id-type="doi">10.1097/RLU.0000000000001818</pub-id><pub-id pub-id-type="pmid">28832377</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luersen</surname><given-names>GF</given-names></name><name><surname>Wei</surname><given-names>W</given-names></name><name><surname>Tamm</surname><given-names>EP</given-names></name><etal></etal></person-group><article-title>Evaluation of magnetic resonance (MR) biomarkers for assessment of response with response evaluation criteria in solid tumors: comparison of the measurements of neuroendocrine tumor liver metastases (NETLM) with various MR sequences and at multiple phases of contrast administration</article-title><source>J Comput Assist Tomogr</source><year>2016</year><volume>40</volume><fpage>717</fpage><lpage>722</lpage><pub-id pub-id-type="doi">10.1097/RCT.0000000000000425</pub-id><pub-id pub-id-type="pmid">27636124</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhosale</surname><given-names>P</given-names></name><name><surname>Kwek</surname><given-names>JW</given-names></name><name><surname>Iyer</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>Follow-up of known carcinoid liver metastases: is respiratory-gated T<sub>2</sub> fast spin-echo enough?</article-title><source>Neuroendocrinology</source><year>2011</year><volume>93</volume><fpage>241</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1159/000326237</pub-id><pub-id pub-id-type="pmid">21474918</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paprottka</surname><given-names>PM</given-names></name><name><surname>Hoffmann</surname><given-names>RT</given-names></name><name><surname>Haug</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres</article-title><source>Cardiovasc Interv Radiol</source><year>2012</year><volume>35</volume><fpage>334</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1007/s00270-011-0248-1</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>CQ</given-names></name><name><surname>Yan</surname><given-names>TD</given-names></name><name><surname>Bester</surname><given-names>L</given-names></name><etal></etal></person-group><article-title>Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases</article-title><source>Br J Surg</source><year>2010</year><volume>297</volume><fpage>537</fpage><lpage>543</lpage><pub-id pub-id-type="doi">10.1002/bjs.6931</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peker</surname><given-names>A</given-names></name><name><surname>Cicek</surname><given-names>O</given-names></name><name><surname>Soydal</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Radioembolization with yttrium-90 resin microspheres for neuroendocrine tumor liver metastases</article-title><source>Diagn Interv Radiol</source><year>2015</year><volume>21</volume><fpage>54</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.5152/dir.2014.14036</pub-id><pub-id pub-id-type="pmid">25430526</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saxena</surname><given-names>A</given-names></name><name><surname>Chua</surname><given-names>TC</given-names></name><name><surname>Bester</surname><given-names>L</given-names></name><etal></etal></person-group><article-title>Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases</article-title><source>Ann Surg</source><year>2010</year><volume>251</volume><fpage>910</fpage><lpage>916</lpage><pub-id pub-id-type="doi">10.1097/SLA.0b013e3181d3d24a</pub-id><pub-id pub-id-type="pmid">20395859</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fidelman</surname><given-names>N</given-names></name><name><surname>Kerlan</surname><given-names>RK</given-names><suffix>Jr</suffix></name><name><surname>Hawkins</surname><given-names>RA</given-names></name><etal></etal></person-group><article-title>Radioembolization with <sup>90</sup>Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy–refractory gastrointestinal cancers: final report of a prospective pilot study</article-title><source>J Gastrointest Oncol</source><year>2016</year><volume>7</volume><fpage>860</fpage><lpage>874</lpage><pub-id pub-id-type="doi">10.21037/jgo.2016.08.04</pub-id><pub-id pub-id-type="pmid">28078110</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>J</given-names></name><name><surname>Rhee</surname><given-names>TK</given-names></name><name><surname>Sato</surname><given-names>KT</given-names></name><etal></etal></person-group><article-title>In vivo diffusion-weighted imaging of liver tumor necrosis in the VX2 rabbit model at 1.5 Tesla</article-title><source>Invest Radiol</source><year>2006</year><volume>41</volume><fpage>410</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1097/01.rli.0000201232.14903.da</pub-id><pub-id pub-id-type="pmid">16523024</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herneth</surname><given-names>AM</given-names></name><name><surname>Guccione</surname><given-names>S</given-names></name><name><surname>Bednarski</surname><given-names>M</given-names></name></person-group><article-title>Apparent diffusion coefficient: a quantitative parameter for in vivo tumor characterization</article-title><source>Eur J Radiol</source><year>2003</year><volume>45</volume><fpage>208</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1016/S0720-048X(02)00310-8</pub-id><pub-id pub-id-type="pmid">12595105</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kukuk</surname><given-names>GM</given-names></name><name><surname>Murtz</surname><given-names>P</given-names></name><name><surname>Traber</surname><given-names>F</given-names></name><etal></etal></person-group><article-title>Diffusion-weighted imaging with acquisition of three <italic>b</italic>-values for response evaluation of neuroendocrine liver metastases undergoing selective internal radiotherapy</article-title><source>Eur Radiol</source><year>2013</year><volume>24</volume><fpage>267</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.1007/s00330-013-3008-6</pub-id><pub-id pub-id-type="pmid">24081644</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>XP</given-names></name><name><surname>Sun</surname><given-names>YS</given-names></name><etal></etal></person-group><article-title>Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases</article-title><source>Radiology</source><year>2008</year><volume>248</volume><fpage>894</fpage><lpage>900</lpage><pub-id pub-id-type="doi">10.1148/radiol.2483071407</pub-id><pub-id pub-id-type="pmid">18710982</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koh</surname><given-names>DM</given-names></name><name><surname>Scurr</surname><given-names>E</given-names></name><name><surname>Collins</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>Predicting response of colorectal hepatic metastasis: value of pretreatment apparent diffusion coefficients</article-title><source>AJR Am J Roentgenol</source><year>2007</year><volume>188</volume><fpage>1001</fpage><lpage>1008</lpage><pub-id pub-id-type="doi">10.2214/AJR.06.0601</pub-id><pub-id pub-id-type="pmid">17377036</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dudeck</surname><given-names>O</given-names></name><name><surname>Zeile</surname><given-names>M</given-names></name><name><surname>Wybranski</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Early prediction of anticancer effects with diffusion-weighted MR imaging in patients with colorectal liver metastases following selective internal radiotherapy</article-title><source>Eur Radiol</source><year>2010</year><volume>20</volume><fpage>2699</fpage><lpage>2706</lpage><pub-id pub-id-type="doi">10.1007/s00330-010-1846-z</pub-id><pub-id pub-id-type="pmid">20563725</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atassi</surname><given-names>B</given-names></name><name><surname>Bangash</surname><given-names>AK</given-names></name><name><surname>Bahrani</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Multimodality imaging following <sup>90</sup>Y radioembolization: a comprehensive review and pictorial essay</article-title><source>Radiographics</source><year>2008</year><volume>28</volume><fpage>81</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1148/rg.281065721</pub-id><pub-id pub-id-type="pmid">18203932</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pieper</surname><given-names>CC</given-names></name><name><surname>Sprinkart</surname><given-names>AM</given-names></name><name><surname>Meyer</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Evaluation of a simplified intravoxel incoherent motion (IVIM) analysis of diffusion-weighted imaging for prediction of tumor size changes and imaging response in breast cancer liver metastases undergoing radioembolization: a retrospective single center analysis</article-title><source>Medicine</source><year>2016</year><volume>95</volume><issue>e3275</issue><fpage>1</fpage><lpage>9</lpage></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lambregts</surname><given-names>DMJ</given-names></name><name><surname>Beets</surname><given-names>GL</given-names></name><name><surname>Maas</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Tumour ADC measurements in rectal cancer: effect of ROI methods on ADC values and interobserver variability</article-title><source>Eur Radiol</source><year>2011</year><volume>21</volume><fpage>2567</fpage><lpage>2574</lpage><pub-id pub-id-type="doi">10.1007/s00330-011-2220-5</pub-id><pub-id pub-id-type="pmid">21822946</pub-id></element-citation></ref></ref-list></back></article>